Coherus Eyes Further Biosimilar Candidates But Urges Caution
As Company Continues To Advance Multiple Candidates
Coherus BioScienes has an extra $200m or so in the bank thanks to a financing round complete last month. The company has committed to building out its pipeline of biosimilar candidates, while eyeing the opportunity to increase its share in the biosimilar pegfilgrastim market.
